Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium

By WebmasterMarch 31, 2017November 1st, 2024No Comments

Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium

See more here

Previous PostGenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017
Next PostQR Pharma, Inc. Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference

Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostGenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017

Next PostQR Pharma, Inc. Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference